Medivation Inc.'s investor call after the close of trading on July 6 proved to be an obvious attempt to encourage higher bids from a group of multiple suitors who are engaged in confidential talks to acquire the San Francisco-based cancer specialist, with one analyst saying the firm's booster efforts behind Phase III PARP inhibitor talazoparib could not have been more transparent.
Having passed on an upgraded purchase offer from Sanofi, Medivation announced on July 5 that the French pharma had dropped its hostile bid for the biotech and was one of several companies that had signed confidential agreements to negotiate terms for a potential buyout. (Also see "Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations" - Scrip, 6 July, 2016
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?